SX-682

Catalog No.S8947 Batch:S894701

Print

Technical Data

Formula

C19H14BF4N3O4S
Molecular Weight 467.20 CAS No. 1648843-04-2
Solubility (25°C)* In vitro DMSO 93 mg/mL (199.05 mM)
Ethanol 93 mg/mL (199.05 mM)
Water ˂1 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description SX-682 is an orally bioavailable small-molecule allosteric inhibitor of CXCR1 and CXCR2 that blocks tumor MDSC recruitment and enhances T cell activation and antitumor immunity.
Targets
CXCR1 [2] CXCR2 [2]
In vivo

Whole tumor accumulation of CXCL1 in vivo in MOC1 and LLC tumors is significantly greater than oral mucosa and normal lung, respectively, and not diminished with SX-682 treatment. Plasma accumulation of CXCL1 is greater in tumor-bearing mice compared with naive for both models and increases following SX-682 treatment. Treatment of mice bearing MOC1 or LLC tumors with SX-682 beginning 10 or 20 days after tumor initiation does not alter CXCR1 or CXCR2 expression on tumor cells in vivo.[2] Following in vivo SX-682 treatment, tumor PMN-MDSC expression of cell surface TGF-β or superoxide dismutase 1/2 genes, responsible for the generation of H2O2, is not significantly altered.[3]

Protocol (from reference)

Animal Study:

[3]
  • Animal Models

    wild-type C57BL/6 mice subcutaneously injected with MOC2 cells (1x105 cells in PBS)

  • Dosages

    500 mg/kg

  • Administration

    Oral gavage

Selleck's SX-682 has been cited by 2 publications

QDPR deficiency drives immune suppression in pancreatic cancer [ Cell Metab, 2024, 36(5):984-999.e8] PubMed: 38642552
Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer [ Nat Commun, 2023, 14(1):4677] PubMed: 37542037

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.